Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 7/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232769 | 0.86 | CALML3 (0.61) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL6365509 | 0.86 | CALML3 (0.61) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL5230590 | 0.85 | MAOA (0.42) | CALML3MAOAMAOBCYP3A4 | |
| SCHEMBL7691878 | 0.85 | MAOA (0.60) | CALML3MAOAMAOBF10 | |
| SCHEMBL7691880 | 0.85 | MAOA (0.60) | CALML3MAOAMAOBF10 | |
| SCHEMBL3042359 | 0.83 | MAOA (0.53) | CALML3MAOAMAOBF10 | |
| SCHEMBL6396969 | 0.82 | MAOA (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL6396961 | 0.82 | MAOA (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL5742018 | 0.81 | MAOA (0.56) | MAOAMAOBCYP3A4 | |
| SCHEMBL5229080 | 0.81 | MAOA (0.56) | MAOAMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| EP-1385844-B1 | OXAZOLIDINONES CONTAINING A SULFONIMID GROUP AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | US | disclosed |
| EP-1286998-B1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| WO-2002081469-A1 | OXAZOLIDINONE-SULFOXIMINES AND -SULFILIMINES AS ANTIBIOTICS | ASTRAZENECA AB (SE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032861-A1 | Oxazolidines containing a sulfonimid group as antibiotics | SULT1E1, STS, OXA1L | CALML3 3934/4885MAOA 963/4885MAOB 357/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | CALML3 4326/4885MAOA 2239/4885MAOB 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.